Form 4: Novavax Director Charles Newton Exercises RSUs

Novavax Director Charles W. Newton acquired 9,520 shares of common stock through the vesting of restricted stock units.

Summary

• Director Charles W. Newton acquired 9,520 shares of Novavax common stock on April 25, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted under the company's equity incentive plan.
• The shares were acquired at a price of $0 per share upon vesting.
• Following this transaction, the reporting person holds 9,520 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director equity compensation.

Positives

• Director alignment with shareholder interests through increased equity ownership.

Negatives

• None identified; this is a routine equity compensation event.

Risks

• None identified; this is a standard disclosure of equity compensation.

Future Outlook

The remaining unvested RSUs are subject to continued service on the Board of Directors, with vesting occurring in one-third increments on the anniversaries of the grant date.

Industry Context

StockSavvy.ai notes that routine RSU vesting for board members is a standard corporate governance practice in the biotechnology sector, reflecting typical long-term incentive structures for independent directors.

Comparison to Industry Standards

• The transaction aligns with standard equity compensation practices for directors at mid-cap biotechnology firms.
• The use of RSUs as a primary component of director compensation is consistent with industry peers such as Moderna or BioNTech.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard equity-based compensation.

Next Steps

• Continued service of the director to satisfy remaining vesting requirements for outstanding RSUs.

Key Dates

Keywords

Novavax, NVAX, Form 4, Insider Trading, Equity Compensation, Director Ownership